You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ):取得獸藥產品批准文號 涉及副豬嗜血桿菌病三價滅活疫苗
格隆匯 12-14 21:18

格隆匯12月14日丨瑞普生物(300119.SZ)公佈,公司空港經濟區分公司近日獲得了由農業農村部核發的獸藥產品批准文號,具體如下:

副豬嗜血桿菌病是由副豬嗜血桿菌(Haemophilus parasuis, HPS)引起的豬多發性漿膜炎和關節炎。HPS主要通過空氣、豬與豬之間的接觸或污染物傳播,患豬和帶菌豬是主要傳染源。副豬嗜血桿菌感染是引起豬場仔豬高死亡率的主要病因之一,主要危害35周齡斷奶仔豬和4月齡以內的育肥豬,發病率一般在30%~40%,死亡率可高達 50%以上,同時副豬嗜血桿菌作為條件性致病菌,常常與豬繁殖與呼吸綜合徵病毒(豬藍耳病)、圓環病毒、豬流感病毒、支原體等病原混合感染,加劇病情的臨牀表現。副豬嗜血桿菌病已經成為全球範圍內危害養豬業健康發展的頭號細菌性疾病,給養豬業帶來巨大的經濟損失。

針對我國副豬嗜血桿菌病的流行情況和商品疫苗的現狀,公司聯合河南科技大學等單位篩選出免疫原性好、遺傳穩定的血清4H4L1株、5H5L3株和12H12L3株優勢血清型菌株作為制苗菌株,採用高密度發酵、超濾純化技術配合優質水佐劑製備疫苗,確保了產品內毒素超低含量控制、抗原純度更高,豬羣應用更安全有效。該產品的研製成功,推動了公司產品的升級、豐富了公司豬類細菌疫苗產品結構,有助於提升公司服務我國養豬業的能力,提高我國豬病防控水平,進而減少抗生素使用量。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account